Climb Bio (CLYM) Competitors $1.26 0.00 (0.00%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. PRME, BNTC, HUMA, AMRN, AARD, AURA, HRTX, OLMA, AQST, and PRTAShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Prime Medicine (PRME), Benitec Biopharma (BNTC), Humacyte (HUMA), Amarin (AMRN), Aardvark Therapeutics (AARD), Aura Biosciences (AURA), Heron Therapeutics (HRTX), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Prime Medicine Benitec Biopharma Humacyte Amarin Aardvark Therapeutics Aura Biosciences Heron Therapeutics Olema Pharmaceuticals Aquestive Therapeutics Prothena Prime Medicine (NYSE:PRME) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership. Which has more volatility and risk, PRME or CLYM? Prime Medicine has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500. Do analysts recommend PRME or CLYM? Prime Medicine currently has a consensus price target of $10.08, suggesting a potential upside of 145.93%. Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 614.29%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Climb Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is PRME or CLYM more profitable? Climb Bio's return on equity of -43.95% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Climb Bio N/A -43.95%-42.94% Do insiders & institutionals hold more shares of PRME or CLYM? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 22.9% of Prime Medicine shares are owned by insiders. Comparatively, 3.2% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, PRME or CLYM? Climb Bio has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M139.97-$198.13M-$1.61-2.55Climb BioN/AN/A-$73.90M-$2.38-0.53 Does the media prefer PRME or CLYM? In the previous week, Prime Medicine had 8 more articles in the media than Climb Bio. MarketBeat recorded 8 mentions for Prime Medicine and 0 mentions for Climb Bio. Prime Medicine's average media sentiment score of 0.89 beat Climb Bio's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Positive Climb Bio Neutral SummaryPrime Medicine beats Climb Bio on 8 of the 14 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.14M$2.87B$5.47B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-0.5320.8026.9920.11Price / SalesN/A286.31428.71119.81Price / CashN/A41.1936.8257.86Price / Book0.407.487.985.56Net Income-$73.90M-$55.04M$3.16B$248.40M7 Day PerformanceN/A2.44%2.38%4.67%1 Month Performance-5.97%1.90%2.17%6.64%1 Year PerformanceN/A4.35%33.81%21.31% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.6316 of 5 stars$1.26flat$9.00+614.3%N/A$85.14MN/A-0.539Gap UpPRMEPrime Medicine4.0534 of 5 stars$2.65+9.5%$10.08+280.5%-25.3%$347.93M$3.85M-1.29234Options VolumeBNTCBenitec Biopharma2.163 of 5 stars$12.35-6.2%$23.83+93.0%+30.5%$345.46M$80K-8.1820Analyst ForecastHigh Trading VolumeHUMAHumacyte2.749 of 5 stars$2.22+1.4%$11.71+427.7%-54.7%$339.71M$1.57M-3.22150News CoverageGap UpAMRNAmarin0.6044 of 5 stars$15.90-1.8%$12.00-24.5%+13.8%$335.25M$228.61M-4.37360AARDAardvark TherapeuticsN/A$13.86-9.9%$31.25+125.5%N/A$333.68MN/A0.0018AURAAura Biosciences1.8841 of 5 stars$6.29-4.3%$22.00+249.8%-14.6%$330.27MN/A-3.3150Positive NewsHRTXHeron Therapeutics3.8245 of 5 stars$2.16+0.5%$5.00+131.5%-25.9%$328.01M$144.29M-36.00300Positive NewsOLMAOlema Pharmaceuticals1.726 of 5 stars$4.56-4.0%$24.50+437.3%-58.0%$325MN/A-2.2770Positive NewsAQSTAquestive Therapeutics1.2446 of 5 stars$3.25flat$10.14+212.1%+53.3%$322.82M$57.56M-5.51160PRTAProthena3.0445 of 5 stars$6.18+3.2%$31.50+409.7%-67.7%$322.42M$135.16M-2.97130High Trading Volume Related Companies and Tools Related Companies Prime Medicine Competitors Benitec Biopharma Competitors Humacyte Competitors Amarin Competitors Aardvark Therapeutics Competitors Aura Biosciences Competitors Heron Therapeutics Competitors Olema Pharmaceuticals Competitors Aquestive Therapeutics Competitors Prothena Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
